Navigation Links
Persons With HIV and Alcohol Problems Co-infected With Hepatitis C
Post Your Comments:
(Date:3/17/2010)... local union reformers and whistleblowers who exposed the union,s corruption and backroom deals and helped healthcare workers protect their democratic right to join a new union ... ... ... ... On Monday, SEIU ...
(Date:3/17/2010)... finds , , WEDNESDAY, March 17 (HealthDay News) -- Gays and ... sexual health such as impotence or low sex drive, a ... more prevalent than one might have guessed." said Roland Dunbrack, ... 18 issue of the New England Journal of Medicine ... in most cases, doesn,t need to be used," said Dunbrack, ...
(Date:3/17/2010)... The world’s largest HVAC/R exposition comes to Las Vegas for ... ... Vegas, NV (Vocus) March 17, 2010, , , , ,Calendar ... February 2 ,Las Vegas Convention Center ,Las Vegas, Nevada , ... Refrigerating Exposition) ,   ...
(Date:3/17/2010)... of Life Care , ... , , ... ... ... BOISE, Idaho , March 17 Idahoans may soon learn someone else,s "conscience" at the worst possible time.  Today, after two days of ...
(Date:3/17/2010)... University of Texas M. D. Anderson Cancer Center ... with advanced or recurrent endometrial cancer, gemcitabine and ... rate in fifty percent of patients. , Jubilee ... Department of Gynecologic Oncology, presented the findings at ... Oncologists, 41st Annual Meeting on Women,s Cancer. , ...
Breaking Medicine News(10 mins):Health News:Democracy on Trial: SEIU's $25 Million Lawsuit Against Union Reformers Goes to Court Monday 2Health News:Democracy on Trial: SEIU's $25 Million Lawsuit Against Union Reformers Goes to Court Monday 3Health News:Gays, Lesbians Excluded From Some Medical Studies 2Health News:2011 AHR EXPO Calendar Listing 2Health News:2011 AHR EXPO Calendar Listing 3Health News:2011 AHR EXPO Calendar Listing 4Health News:Idaho Passes Bill to Put 'Conscience' Between Patients & End of Life Rights 2Health News:Idaho Passes Bill to Put 'Conscience' Between Patients & End of Life Rights 3Health News:Researchers find new chemotherapy combination shows promise in endometrial cancer 2
... services has become an increasingly important issue with the ... ,Four separate articles in the latest ... related to the implementation of the program. ... Head of Colorectal Medicine and Genetics at Royal Melbourne ...
... father passed on a rare side effect of the smallpox vaccination ... , The boy who is currently being treated at University ... 80 percent of his body. ,Eczema vaccinatum is an ... who receive the shot or their close contacts. , ...
... a ray of hope to persons suffering from aniridia - a ... 1,000 people in the UK alone, suffer from this rare ... cells that can rejuvenate tissue in the eye. ,Sufferers ... or cataracts - when they are young. , Aniridia ...
... be gold, according to the journal Proceedings of the National ... vaccines are losing their efficiency in// preventing tuberculosis, and scientists ... , The scientists led by Dr. Roland Brosch ... or bacillus Calmette Guerin vaccines used in immunization ...
... the ill effects of second-hand tobacco smoke than their white ... with asthma. ,Black children who were exposed to ... levels in their hair and blood than white children with ... metabolize or break down nicotine more slowly than white children," ...
... is the first in the state to perform a ... stimulate regeneration of the heart muscle after a// heart ... centers in the country providing this new treatment modality ... Amorcyte, a privately funded cell-therapy company studying stem cells ...
Other Medicine News:Health News:Bowel Cancer Screening Program 2Health News:Toddler Infected With Rare Side Effect of Smallpox Vaccine 2Health News:TB Vaccines: Ring Out the New, Bring in the Old 2Health News:Vanderbilt Performs State's First Stem Cell Heart Regeneration Therapy 2Health News:Vanderbilt Performs State's First Stem Cell Heart Regeneration Therapy 3
(Date:3/17/2010)... , March 17 Zogenix, ... that it has initiated a pivotal Phase 3 ... formulation of hydrocodone without acetaminophen.  ZX002 is being ... pain in individuals who require around-the-clock opioid therapy ... most widely prescribed drug in the United ...
(Date:3/17/2010)... Executives from pharmaceutical companies and health care payer and provider organizations ... discuss mutually beneficial partnerships that, if implemented, could replace the traditional model of ... on quantifying and communicating total value. , ... ... ...
(Date:3/17/2010)... Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ), the leader in antisense therapeutics, today announced that management will present a company overview at Barclays, 2010 ... ... , , ... ... ...
Breaking Medicine Technology:Zogenix Initiates Pivotal Phase 3 Clinical Trial for Novel Formulation of Oral Controlled-Release Hydrocodone 2Zogenix Initiates Pivotal Phase 3 Clinical Trial for Novel Formulation of Oral Controlled-Release Hydrocodone 3Zogenix Initiates Pivotal Phase 3 Clinical Trial for Novel Formulation of Oral Controlled-Release Hydrocodone 4Drug Makers Discuss New Ways to Trim Health Care Costs at ZS Associates and eyeforpharma Forum 2Drug Makers Discuss New Ways to Trim Health Care Costs at ZS Associates and eyeforpharma Forum 3Drug Makers Discuss New Ways to Trim Health Care Costs at ZS Associates and eyeforpharma Forum 4Drug Makers Discuss New Ways to Trim Health Care Costs at ZS Associates and eyeforpharma Forum 5Drug Makers Discuss New Ways to Trim Health Care Costs at ZS Associates and eyeforpharma Forum 6Drug Makers Discuss New Ways to Trim Health Care Costs at ZS Associates and eyeforpharma Forum 7Drug Makers Discuss New Ways to Trim Health Care Costs at ZS Associates and eyeforpharma Forum 8Isis Pharmaceuticals to Present at the Barclays Capital 2010 Global Healthcare Conference 2Tampa Bay Radiation Oncology Announces New Full Service Center at Bruce B Downs 53170 1C O R R E C T I O N Osteotech Inc 53169 1C O R R E C T I O N Osteotech Inc 53169 2C O R R E C T I O N Osteotech Inc 53169 3C O R R E C T I O N Osteotech Inc 53169 4C O R R E C T I O N Osteotech Inc 53169 5C O R R E C T I O N Osteotech Inc 53169 6C O R R E C T I O N Osteotech Inc 53169 7C O R R E C T I O N Osteotech Inc 53169 8C O R R E C T I O N Osteotech Inc 53169 9Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 1Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 2Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 3Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 4Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 5Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 6Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 7Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 8Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 9Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 10Oncolytics Biotech 28R 29 Inc Announces 2009 Second Quarter Results 13264 11
... 12 Recent guidelines published by the,Clinical Resource ... use of bioimpedance technology for the early assessment ... titled "Guidelines for,the Diagnosis, Assessment and Management of ... patients and healthcare professionals that,reviewed the evidence for ...
... Md., June 12 ,Micromet, Inc. (Nasdaq: MITI ... has started treatment in a multi-center, phase 2 ... in,patients with adult acute lymphoblastic leukemia (ALL). Blinatumomab ... antigen, which is only expressed,on B cells. The ...
Other Medicine Technology:Published Guidelines Further Support Use of Bioimpedance Measurement Technology for Early Assessment of Lymphedema 2Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia 2Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia 3Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia 4Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia 5Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia 6
...
...
...
The Doro Halo retractor system is designed for all neurosurgical applications where retraction of the brain tissue and an armrest is required....
Medicine Products: